Q-omics provides the consensus-scored DEPDC5 profile across patient tissues and cancer cell-line models. DEPDC5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DEPDC5 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, DEPDC5 RNA expression shows 20,682 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where DEPDC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEPDC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEPDC5 survival associations across molecular data types. DEPDC5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEPDC5 RNA expression–survival associations across cancer types. High DEPDC5 expression shows unfavorable associations in ACC, UVM and KIRP, but favorable associations in HNSC, LUSC and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DEPDC5 RNA expression.
This table summarizes DEPDC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DEPDC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEPDC5 shows lower tumor expression in THCA and higher tumor expression in HNSC, KICH, LIHC, BLCA and LUSC. The HNSC box plot shows higher DEPDC5 RNA expression in tumor versus normal tissue (log2 FC = +0.392, t-test p < 0.001).
This table shows molecular features associated with DEPDC5 in patient tissues and cancer cell lines. In patient samples, DEPDC5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DEPDC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
